Perrigo Co PLC (PRGO)
31.22
+0.74
(+2.41%)
USD |
NYSE |
Apr 24, 16:00
31.00
-0.22
(-0.72%)
After-Hours: 18:53
Perrigo Research and Development Expense (Quarterly): 29.60M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 29.60M |
| September 30, 2023 | 29.60M |
| June 30, 2023 | 32.20M |
| March 31, 2023 | 31.10M |
| December 31, 2022 | 32.60M |
| September 30, 2022 | 29.80M |
| June 30, 2022 | 31.50M |
| March 31, 2022 | 29.30M |
| December 31, 2021 | 30.30M |
| September 30, 2021 | 27.60M |
| June 30, 2021 | 33.00M |
| March 31, 2021 | 31.10M |
| December 31, 2020 | 33.00M |
| September 30, 2020 | 30.40M |
| June 30, 2020 | 30.40M |
| March 31, 2020 | 27.90M |
| December 31, 2019 | -8.80M |
| September 30, 2019 | 44.00M |
| June 30, 2019 | 43.90M |
| March 31, 2019 | 40.20M |
| December 31, 2018 | 44.60M |
| September 30, 2018 | 43.70M |
| June 30, 2018 | 91.90M |
| March 31, 2018 | 38.40M |
| December 31, 2017 | 46.90M |
| Date | Value |
|---|---|
| September 30, 2017 | 38.40M |
| June 30, 2017 | 42.60M |
| March 31, 2017 | 39.80M |
| December 31, 2016 | 41.50M |
| September 30, 2016 | 50.20M |
| June 30, 2016 | 47.00M |
| March 31, 2016 | 45.30M |
| December 31, 2015 | 46.60M |
| September 30, 2015 | 41.60M |
| June 30, 2015 | 62.60M |
| March 31, 2015 | 35.40M |
| December 31, 2014 | 53.20M |
| September 30, 2014 | 36.60M |
| June 30, 2014 | 38.00M |
| March 31, 2014 | 44.70M |
| December 31, 2013 | 37.50M |
| September 30, 2013 | 32.30M |
| June 30, 2013 | 31.00M |
| March 31, 2013 | 28.50M |
| December 31, 2012 | 28.30M |
| September 30, 2012 | 27.40M |
| June 30, 2012 | 27.06M |
| March 31, 2012 | 27.95M |
| December 31, 2011 | 31.15M |
| September 30, 2011 | 19.64M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-8.80M
Minimum
Dec 2019
44.00M
Maximum
Sep 2019
29.92M
Average
30.40M
Median
Jun 2020
Research and Development Expense (Quarterly) Benchmarks
| Alkermes PLC | -20.76M |
| Endo International PLC | 28.14M |
| Jazz Pharmaceuticals PLC | 216.61M |
| Medtronic PLC | 695.00M |
| Iterum Therapeutics PLC | 9.744M |